{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:30:19Z","timestamp":1794562219380,"version":"4.9.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ajo.2026.05.038","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T23:57:51Z","timestamp":1780012671000},"page":"273-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ocular Safety Signals of Fibroblast Growth Factor Receptor Inhibitors in Postmarketing Surveillance"],"prefix":"10.1016","volume":"289","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9241-6428","authenticated-orcid":false,"given":"ABDELRAHMAN","family":"ABU OSBA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3193-7019","authenticated-orcid":false,"given":"SYED","family":"AHMAD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ROAA","family":"ABU OSBA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ABD EL AZIZ","family":"HENDY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7567-8962","authenticated-orcid":false,"given":"MOSTAFA","family":"BONDOK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2692-0759","authenticated-orcid":false,"given":"ANDREW","family":"MIHALACHE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RADHA P.","family":"KOHLY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DAVID","family":"WONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RAJEEV H.","family":"MUNI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARKO M.","family":"POPOVIC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ajo.2026.05.038_bib0001","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.tips.2025.09.004","article-title":"Next-generation isoform-selective fibroblast growth factor receptor inhibitors","volume":"46","author":"Chen","year":"2025","journal-title":"Trends Pharmacol Sci"},{"issue":"21","key":"10.1016\/j.ajo.2026.05.038_bib0002","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajo.2026.05.038_bib0003","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14737140.2023.2192930","article-title":"Pemigatinib for the treatment of myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"23","author":"Freyer","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"10.1016\/j.ajo.2026.05.038_bib0004","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/medicina57050458","article-title":"Targeted therapies in advanced cholangiocarcinoma: a focus on FGFR inhibitors","volume":"57","author":"Rizzo","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.ajo.2026.05.038_bib0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.survophthal.2023.09.007","article-title":"Ocular toxicities of fibroblast growth factor receptor inhibitors: a review","volume":"69","author":"Hsu","year":"2024","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.05.038_bib0006","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ajo.2026.05.038_bib0007","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with fgfr2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ajo.2026.05.038_bib0008","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a Phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ajo.2026.05.038_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/11206721231220334","article-title":"Pan fibroblast growth factor receptor inhibitor associated retinopathy","volume":"34","author":"Paris","year":"2024","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.05.038_bib0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.15353\/cjo.v84i4.4349","article-title":"Erdafitinib-associated Central serous chorioretinopathy: a case report","volume":"84","author":"Blanchard","year":"2022","journal-title":"Can J Optom"},{"key":"10.1016\/j.ajo.2026.05.038_bib0011","article-title":"Case report: pemigatinib-induced retinopathy: a serial examination of subretinal fluid secondary to an FGFR inhibitor","volume":"3","author":"Barmas-Alamdari","year":"2024","journal-title":"Front Ophthalmol (Lausanne)"},{"issue":"1","key":"10.1016\/j.ajo.2026.05.038_bib0012","article-title":"Data mining and safety analysis of FGFR tyrosine kinase inhibitors based on the FAERS database","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ajo.2026.05.038_bib0013","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/ICB.0000000000001354","article-title":"Irreversible retinal pigment epithelium toxicity associated with fibroblast growth factor receptor inhibitor therapy","volume":"18","author":"Houghton","year":"2024","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.ajo.2026.05.038_bib0014","unstructured":"U.S. Food and Drug Administration. FDA adverse event reporting system (FAERS): latest data and access. Updated 2024 Accessed November 14, 2025. Available from: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers"},{"key":"10.1016\/j.ajo.2026.05.038_bib0015","article-title":"OpenVigil 2.1: an open-source, validated pharmacovigilance tool for signal detection in the FDA adverse event reporting system","volume":"14","author":"B\u00f6hm","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ajo.2026.05.038_bib0016","unstructured":"Balversa (erdafitinib) tablets [prescribing information]. Janssen pharmaceutical companies; approved April 2019. U.S. Food Drug Adm Website. Accessed December 4, 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212018s000lbl.pdf."},{"key":"10.1016\/j.ajo.2026.05.038_bib0017","unstructured":"Pemazyre (pemigatinib) tablets [prescribing information]. Incyte corporation; revised August 2022. U.S. Food Drug Adm Website. Accessed December 4, 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213736s002lbl.pdf."},{"key":"10.1016\/j.ajo.2026.05.038_bib0018","unstructured":"Lytgobi (futibatinib) tablets [prescribing information]. Taiho oncology, inc.; revised September 2022. U.S. Food Drug Adm Website. Accessed December 4, 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214801s000lbl.pdf."},{"issue":"3","key":"10.1016\/j.ajo.2026.05.038_bib0019","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.oret.2025.08.018","article-title":"Association of anti-VEGF therapy with reported ocular adverse events: a global pharmacovigilance analysis","volume":"10","author":"Lakhani","year":"2026","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2026.05.038_bib0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ajo.2025.03.023","article-title":"Drugs associated with floppy Iris syndrome: a real-world population-based study","volume":"275","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.05.038_bib0021","unstructured":"MedDRA; MSSO. Medical dictionary for regulatory activities (MedDRA): introductory guide version 27.1. Int Counc Harmon. 2024. Accessed November 14, 2025. Available at: https:\/\/alt.meddra.org\/files_acrobat\/intguide_27_1_english.pdf"},{"issue":"6","key":"10.1016\/j.ajo.2026.05.038_bib0022","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.ajo.2026.05.038_bib0023","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ajo.2026.05.038_bib0024","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajo.2026.05.038_bib0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.survophthal.2007.02.008","article-title":"Retinal pigment epithelial detachment","volume":"52","author":"Zayit-Soudry","year":"2007","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.05.038_bib0026","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3928\/23258160-20251014-01","article-title":"Erdafitinib-associated subretinal fluid in a 75-year-old man with vitreomacular traction","volume":"57","author":"Bisarya","year":"2026","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"6","key":"10.1016\/j.ajo.2026.05.038_bib0027","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3928\/23258160-20230501-01","article-title":"Dose-dependent and reversible serous retinal detachments in fibroblast growth factor receptor inhibitor-associated retinopathy","volume":"54","author":"Parikh","year":"2023","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ajo.2026.05.038_bib0028","article-title":"Erdafitinib-associated retinal alterations and rapid onset bilateral white cataracts","volume":"34","author":"Sassine","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"6","key":"10.1016\/j.ajo.2026.05.038_bib0029","article-title":"Erdafitinib-induced bilateral multifocal serous retinal detachments and severe dry eye related unilateral peripheral ulcerative keratitis in a patient with metastatic urothelial carcinoma","volume":"11","author":"Kayaba\u015fi","year":"2024","journal-title":"Eur J Case Rep Intern Med"},{"issue":"8","key":"10.1016\/j.ajo.2026.05.038_bib0030","article-title":"Early optical coherence tomography signs of Erdafitinib-induced retinopathy","volume":"16","author":"Ercanbrack","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.ajo.2026.05.038_bib0031","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000519275","article-title":"Reversible retinopathy associated with fibroblast growth factor receptor inhibitor","volume":"13","author":"Patel","year":"2022","journal-title":"Case Rep Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.05.038_bib0032","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/ICB.0000000000001354","article-title":"Irreversible retinal pigment epithelium toxicity associated with fibroblast growth factor receptor inhibitor therapy","volume":"18","author":"Houghton","year":"2024","journal-title":"Retin Cases Brief Rep"},{"issue":"6","key":"10.1016\/j.ajo.2026.05.038_bib0033","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/ICB.0000000000001468","article-title":"Subretinal fluid associated with pemigatinib therapy for cholangiocarcinoma: a case report and literature review","volume":"18","author":"Caranfa","year":"2024","journal-title":"Retin Cases Brief Rep"},{"issue":"2","key":"10.1016\/j.ajo.2026.05.038_bib0034","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/ICL.0000000000001058","article-title":"Eyes on the lid: the impact of fibroblast growth factor receptor targeting drug on human meibomian gland","volume":"50","author":"Chen","year":"2024","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.ajo.2026.05.038_bib0035","article-title":"Trichiasis and dry eye syndrome in two patients on novel fibroblast growth factor receptor inhibitor therapies","volume":"19","author":"Vinson","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"3","key":"10.1016\/j.ajo.2026.05.038_bib0036","doi-asserted-by":"crossref","first-page":"847","DOI":"10.4143\/crt.2023.1197","article-title":"Global expanded access program for pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma and fibroblast growth factor receptor gene alterations","volume":"56","author":"Lindley","year":"2024","journal-title":"Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ajo.2026.05.038_bib0037","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/ICL.0000000000001058","article-title":"Eyes on the lid: the impact of fibroblast growth factor receptor targeting drug on human meibomian gland","volume":"50","author":"Chen","year":"2024","journal-title":"Eye Contact Lens"},{"issue":"5","key":"10.1016\/j.ajo.2026.05.038_bib0038","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1167\/iovs.16-21204","article-title":"Fibroblast growth factor receptor 2 (FGFR2) is required for meibomian gland homeostasis in the adult mouse","volume":"58","author":"Reneker","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2026.05.038_bib0039","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ophtha.2014.12.018","article-title":"Increased tear fluid production as a compensatory response to meibomian gland loss: a multicenter cross-sectional study","volume":"122","author":"Arita","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2026.05.038_bib0040","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/07853890.2022.2056238","article-title":"Lipid layer thickness decrease due to meibomian gland dysfunction leads to tear film instability and reflex tear secretion","volume":"54","author":"Kim","year":"2022","journal-title":"Ann Med"},{"issue":"12","key":"10.1016\/j.ajo.2026.05.038_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122968","article-title":"FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice","volume":"13","author":"Kommalapati","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ajo.2026.05.038_bib0042","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamaophthalmol.2021.3331","article-title":"Clinical and morphologic characteristics of fibroblast growth factor receptor inhibitor\u2013associated retinopathy","volume":"139","author":"Francis","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2026.05.038_bib0043","first-page":"149","article-title":"Fibroblast growth factor receptor (FGFR) and candidate signaling molecule distribution within rat and human retina","volume":"8","author":"Kinkl","year":"2002","journal-title":"Mol Vis"},{"issue":"12","key":"10.1016\/j.ajo.2026.05.038_bib0044","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","article-title":"Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.05.038_bib0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2024.12.028","article-title":"Pathogenic mechanisms of immune checkpoint inhibitor (ICI)-associated retinal and choroidal adverse reactions","volume":"272","author":"Haliyur","year":"2025","journal-title":"Am J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:18:37Z","timestamp":1794561517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426002928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":45,"alternative-id":["S0002939426002928"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.05.038","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Safety Signals of Fibroblast Growth Factor Receptor Inhibitors in Postmarketing Surveillance","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.05.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}